Skip Navigation

European Heart Journal 2004 25(16):1371-1373; doi:10.1016/j.ehj.2004.06.027
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van Hemel, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Hemel, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Quinidine rehabilitated and more lessons from the PAFAC and SOPAT anti-arrhythmic drug trials for the prevention of paroxysmal atrial fibrillation

Norbert van Hemel*

Heart Lung Center Utrecht, Department of Cardiology, St. Antonius Hospital, Nieuwegen, The Netherlands

* Correspondence to: Norbert van Hemel, Heart Lung Center Utrecht, Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegen, The Netherlands. Tel.: +31-30-6099111; fax: +31-30-6034420 (E-mail: n.m.vanhemel@hetnet.nl).

The first 150 words of the full text of this article appear below.

This editorial refers to "Suppression of paroxysmal atrial tachyarrhythmias —results of the SOPAT trial"{dagger}

Although two recently published studies1,2 showed that rate control of persistent atrial fibrillation (AF) is not inferior to rhythm control, the maintenance of sinus rhythm and suppression of AF remain desirable in selected cases, especially in very symptomatic and often young patients.3 After successful electrical cardioversion or repeated bouts of AF, the selection, dosage and timing of an anti-arrhythmic treatment to prevent new AF recurrences, as well as the decision whether to hospitalise the patient for its initiation, constitute a series of difficult decisions in terms of efficacy, safety and cost-effectiveness. One of the oldest anti-arrhythmic drugs to prevent AF is quinidine but in the past decade its efficacy and safety was so heavily refuted that the frequency of description of this drug dropped dramatically.4 Of note, it has become clear that the diagnosis of recurrences . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Suppression of paroxysmal atrial tachyarrhythmias — results of the SOPAT trial
Monica Patten, Renke Maas, Peter Bauer, Berndt Lüderitz, Frank Sonntag, Miroslaw Dluzniewski, Robert Hatala, Grzegorz Opolski, Hans-Walter Müller, Thomas Meinertz, and for the SOPAT Investigators
EHJ 2004 25: 1395-1404. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
H. H. Veloso and A. A.V. de Paola
Quinidine plus verapamil vs. quinidine alone to prevent recurrences of atrial fibrillation
Eur. Heart J., August 1, 2005; 26(15): 1568 - 1569.
[Full Text] [PDF]